Skip to main content

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference being held from August 7-10, 2023 in Boston.

Details of the event are as follows:

Date: Wednesday, August 9, 2023

Time: 1:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.82
-10.55 (-4.10%)
AAPL  342.56
-6.65 (-1.90%)
AMD  424.39
-64.80 (-13.25%)
BAC  47.04
-1.53 (-3.15%)
GOOG  264.00
-7.02 (-2.59%)
META  560.84
-35.38 (-5.93%)
MSFT  484.52
-13.78 (-2.77%)
NVDA  125.53
-20.45 (-14.01%)
ORCL  101.19
-9.38 (-8.48%)
TSLA  345.82
-28.59 (-7.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.